Shandong Jinpharm Co.,Ltd

Company snapshot

Shandong University is a pharma organization headquartered in CN. Primary therapeutic focus areas include Helicobacter Pylori, Type 2 Diabetes, Sedation. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1), approved (1).

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Shandong Jinpharm Co.,Ltd. Not investment advice.

• What is Shandong Jinpharm Co.,Ltd?

  Shandong University is a pharma organization headquartered in CN. Primary therapeutic focus areas include Helicobacter Pylori, Type 2 Diabetes, Sedation. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Cli

• Is Shandong Jinpharm Co.,Ltd publicly traded?

  Shandong Jinpharm Co.,Ltd appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Shandong Jinpharm Co.,Ltd develop or market?

  We link 5 drug profile(s) where Shandong Jinpharm Co.,Ltd is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/shandong-university#company-drugs.

• What are the latest developments for Shandong Jinpharm Co.,Ltd?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Shandong Jinpharm Co.,Ltd focus on?

  Shandong Jinpharm Co.,Ltd focuses on Helicobacter Pylori, Type 2 Diabetes, Sedation based on our analysis of their pipeline programs and drug development activities.